WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with some downsides takes its place.
As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the program continues. In the two years since the first case challenging the program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results